PMID- 20231676 OWN - NLM STAT- MEDLINE DCOM- 20100429 LR - 20220410 IS - 1527-7755 (Electronic) IS - 0732-183X (Linking) VI - 28 IP - 11 DP - 2010 Apr 10 TI - Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. PG - 1963-72 LID - 10.1200/JCO.2009.26.3541 [doi] AB - Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas. FAU - Wen, Patrick Y AU - Wen PY AD - Center for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA. pwen@partners.org FAU - Macdonald, David R AU - Macdonald DR FAU - Reardon, David A AU - Reardon DA FAU - Cloughesy, Timothy F AU - Cloughesy TF FAU - Sorensen, A Gregory AU - Sorensen AG FAU - Galanis, Evanthia AU - Galanis E FAU - Degroot, John AU - Degroot J FAU - Wick, Wolfgang AU - Wick W FAU - Gilbert, Mark R AU - Gilbert MR FAU - Lassman, Andrew B AU - Lassman AB FAU - Tsien, Christina AU - Tsien C FAU - Mikkelsen, Tom AU - Mikkelsen T FAU - Wong, Eric T AU - Wong ET FAU - Chamberlain, Marc C AU - Chamberlain MC FAU - Stupp, Roger AU - Stupp R FAU - Lamborn, Kathleen R AU - Lamborn KR FAU - Vogelbaum, Michael A AU - Vogelbaum MA FAU - van den Bent, Martin J AU - van den Bent MJ FAU - Chang, Susan M AU - Chang SM LA - eng PT - Journal Article DEP - 20100315 PL - United States TA - J Clin Oncol JT - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JID - 8309333 SB - IM CIN - J Clin Oncol. 2011 Feb 20;29(6):e148; author reply e149. PMID: 21189392 CIN - J Clin Oncol. 2011 Mar 20;29(9):e245-6; author reply e247. PMID: 21282544 MH - Brain Neoplasms/*diagnosis/*therapy MH - Clinical Trials as Topic MH - Diagnostic Imaging/methods/*standards MH - Glioma/*diagnosis/*therapy MH - Guidelines as Topic MH - Humans MH - Prognosis MH - Treatment Outcome EDAT- 2010/03/17 06:00 MHDA- 2010/04/30 06:00 CRDT- 2010/03/17 06:00 PHST- 2010/03/17 06:00 [entrez] PHST- 2010/03/17 06:00 [pubmed] PHST- 2010/04/30 06:00 [medline] AID - JCO.2009.26.3541 [pii] AID - 10.1200/JCO.2009.26.3541 [doi] PST - ppublish SO - J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.